Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(4-(4-(4-hydroxy-piperidin-1-yl)-phenylamino)-5-oxo-5,6-dihydro-pyrimido(4,5-d)pyridazin-2-yl)-piperidin-4-yl-acetonitrile
2. 4-piperidineacetonitrile, 1-(5,6-dihydro-4-((4-(4-hydroxy-1-piperidinyl)phenyl)amino)-5-oxopyrimido(4,5-d)pyridazin-2-yl)-
3. Asn-002
4. Asn002
1. Asn002
2. Asn-002
3. 1425381-60-7
4. Gusacitinib [inn]
5. Gusacitinib [usan]
6. En3351
7. 4801qyw816
8. En-3351
9. 2-[1-[4-[4-(4-hydroxypiperidin-1-yl)anilino]-5-oxo-6h-pyrimido[4,5-d]pyridazin-2-yl]piperidin-4-yl]acetonitrile
10. 1-(4-(4-(4-hydroxy-piperidin-1-yl)-phenylamino)-5-oxo-5,6-dihydro-pyrimido(4,5-d)pyridazin-2-yl)-piperidin-4-yl-acetonitrile
11. 4-piperidineacetonitrile, 1-(5,6-dihydro-4-((4-(4-hydroxy-1-piperidinyl)phenyl)amino)-5-oxopyrimido(4,5-d)pyridazin-2-yl)-
12. Gusacitinib (usan/inn)
13. Gusacitinib [who-dd]
14. Chembl4594275
15. Schembl14717111
16. Unii-4801qyw816
17. Gtpl10000
18. Asn-002asn-002
19. Bcp31675
20. Ex-a2668
21. Nsc818003
22. Who 10976
23. Nsc-818003
24. Example 189 [wo2013028818a1]
25. Hy-103018
26. Asn-002; Asn 002; Asn002
27. Cs-0023113
28. D11676
29. F78024
30. 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile
| Molecular Weight | 460.5 g/mol |
|---|---|
| Molecular Formula | C24H28N8O2 |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 460.23352217 g/mol |
| Monoisotopic Mass | 460.23352217 g/mol |
| Topological Polar Surface Area | 130 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 775 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Undisclosed Brand Name: ASN-002
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Sanofi
Deal Size: $627.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 23, 2025
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $627.6 million
Deal Type : Licensing Agreement
Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor
Details : Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study.
Product Name : ASN-002
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 23, 2025
Details:
Asana BioSciences will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral JAK kinase family and SYK tyrosine kinase inhibitor gusacitinib in adult patients with moderate-to-severe chronic hand eczema.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 21, 2021
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Asana BioSciences will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral JAK kinase family and SYK tyrosine kinase inhibitor gusacitinib in adult patients with moderate-to-severe chro...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2021
Details:
Gusacitinib achieved rapid, dose-dependent, clinically meaningful, and statistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy as early as 2 weeks and the effects were sustained for the duration of the study.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2020
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gusacitinib achieved rapid, dose-dependent, clinically meaningful, and statistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy as early as 2 weeks and the effects were sustained for the durati...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2020
Details:
ASN-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2020
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
Details : ASN-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 04, 2020
Details:
The topline results show that gusacitinib achieved a dose dependent, clinically meaningful, andstatistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2020
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The topline results show that gusacitinib achieved a dose dependent, clinically meaningful, andstatistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2020
Details:
ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 02, 2018
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
Details : ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2018
Details:
ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2018
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Details : ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 31, 2018
Details:
ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2018
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
Details : ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2018
Details:
ASN-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 05, 2017
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASN-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 05, 2017
Details:
ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Gusacitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2017
Lead Product(s) : Gusacitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis
Details : ASN002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2017
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
61
PharmaCompass offers a list of Gusacitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gusacitinib manufacturer or Gusacitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gusacitinib manufacturer or Gusacitinib supplier.
A Gusacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gusacitinib, including repackagers and relabelers. The FDA regulates Gusacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gusacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gusacitinib supplier is an individual or a company that provides Gusacitinib active pharmaceutical ingredient (API) or Gusacitinib finished formulations upon request. The Gusacitinib suppliers may include Gusacitinib API manufacturers, exporters, distributors and traders.
Gusacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gusacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gusacitinib GMP manufacturer or Gusacitinib GMP API supplier for your needs.
A Gusacitinib CoA (Certificate of Analysis) is a formal document that attests to Gusacitinib's compliance with Gusacitinib specifications and serves as a tool for batch-level quality control.
Gusacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Gusacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gusacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Gusacitinib EP), Gusacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gusacitinib USP).
